Decreased therapeutic effects of noscapine combined with imatinib mesylate on human glioblastoma in vitro and the effect of midkine

dc.contributor.author	Erguven, M.
dc.contributor.author	Bilir, A.
dc.contributor.author	Yazihan, N.
dc.contributor.author	Ermis, E.
dc.contributor.author	Sabanci, A.
dc.contributor.author	Aktas, E.
dc.contributor.author	Aras, Y.
dc.contributor.author	Alpman, V.
dc.date.accessioned	2021-12-21T08:42:00Z
dc.date.available	2021-12-21T08:42:00Z
dc.date.issued	2011
dc.identifier.issn	14752867
dc.identifier.uri	https://doi.org/10.1186/1475-2867-11-18
dc.identifier.uri	http://dspace.yeniyuzyil.edu.tr:8080/xmlui/handle/20.500.12629/1570
dc.description.abstract	Background: Glioblastoma (GBM) develops resistance to the advances in chemotherapy leading to poor prognosis and life quality. Consequently, new treatment modalities are needed. Our aims were to investigate the effects of combined noscapine (NOS) and imat
dc.description.sponsorship	This work was supported by Scientific Research Projects Coordination Unit of Istanbul University (Project number: T988/06102006). The authors of this paper would like to thank the investigators for their generous gifts and/or reagents.
dc.language.iso	English
dc.rights	All Open Access, Gold, Green
dc.title	Decreased therapeutic effects of noscapine combined with imatinib mesylate on human glioblastoma in vitro and the effect of midkine
dc.type	Article
dc.relation.journal	Cancer Cell International
dc.identifier.volume	11
dc.identifier.doi	10.1186/1475-2867-11-18
dc.relation.volume	11